Axsome Therapeutics Inc (AXSM)

[BioSpecialist]

$5 is coming very close , good results will push this low float gem close or above $10 in the blink of an eye .GL

Should You Invest In Axsome Therapeutics? Monday, May 8, 2017
http://www.talkmarkets.com/content/stocks--equities/should-you-invest-in-axsome-therapeutics?post=134346

Final Thoughts

Axsome is very interesting to me. The company has four active Phase 3 clinical trials with two drug candidates. AXS-05 targets a host of mechanisms in the CNS that are clinically and commercially proven to be effective for the treatment of depression and agitation. The concept with AXS-05 is that dextromethorphan is pretty darn effective in treating depression, but has such poor bioavailability that it is hardly used. Bupropion synergistically improves the uptake of BM while providing baseline antidepressant effects. AXS-02 is an oral formulation of a well know bisphosphonate known to improve pain in CRPS and knee OA.

I like the fact that Axsome has good insider ownership, plenty of cash, drugs with proven mechanisms of action, strong IP, and plenty of catalysts. Data from COAST-1 is expected in the Q3-2017. That's the first catalyst up for the company. CREATE-1 and STRIDE-1 are up in the Q4-2017 and Q1-2018, respectively. If the company goes 3-for-3, this stock will be north of $15.

-------------------

Recommendation by Aegis (TGT $20):

Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Therapeutics (NASDAQ: AXSM) after the company reported financial results for the quarter ended March 31, 2017. The analyst noted that although Axsome reported revenue in-line with consensus estimates, the focus remains on upcoming catalysts such as the company’s ongoing clinical trials. Since February 2017, the company’s AXS-05 has received fast track designation from the FDA for the treatment of Alzheimer’s disease (AD) agitation and treatment resistant depression (TRD). Topline data from the TRD treatment study is expected in the first quarter of 2018. Additionally, Axsome is developing AXS-02 in three separate phase 3 clinical programs, including chronic low back pain associated with modic changes and complex regional pain syndrome, with interim data expected in the fourth quarter of 2017, as well as knee osteoarthritis associated with bone marrow lesions, with interim data expected in the third quarter of 2017.

-----

Recommendation by BTIG (TGT $14 ):

Axsome Therapeutics initiated with a Buy at BTIG BTIG analyst Robert Hazlett started coverage of Axsome with a $14 price target and a Buy rating. The analyst says that the company's AXS-05 combination is unique and could treat a number of disorders. He notes that data on the combination's impact on treatment-resistant depression is due in early 2018. Tgh analyst adds that the company's AXS-02 drug "is a novel approach to the treatment of pain," and reports that data on the drug is due out in Q3 and Q4.

-----
Axsome Therapeutics: ~$4 Biotech Stock A Worthy Investment? May 15 ,2017
https://seekingalpha.com/instablog/498952-bret-jensen/4989021-axsome-therapeutics-4-biotech-stock-worthy-investment